C van Pottelsberghe

1.5k total citations · 1 hit paper
13 papers, 1.2k citations indexed

About

C van Pottelsberghe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, C van Pottelsberghe has authored 13 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Surgery. Recurrent topics in C van Pottelsberghe's work include Sarcoma Diagnosis and Treatment (4 papers), Cancer Treatment and Pharmacology (2 papers) and Gastric Cancer Management and Outcomes (2 papers). C van Pottelsberghe is often cited by papers focused on Sarcoma Diagnosis and Treatment (4 papers), Cancer Treatment and Pharmacology (2 papers) and Gastric Cancer Management and Outcomes (2 papers). C van Pottelsberghe collaborates with scholars based in Netherlands, Belgium and France. C van Pottelsberghe's co-authors include Desmond Curran, Greet Van den Berghe, H G Hers, T. Pignon, E.J. Maher, Peter Fayers, A.-L. Söderholm, Randall P. Morton, Kristin Bjordal and Alexander de Graeff and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical Journal and Annals of Oncology.

In The Last Decade

C van Pottelsberghe

13 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients

2000 630 citations Kristin Bjordal, Alexander de Graeff et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by C van Pottelsberghe

Since Specialization

Citations

This map shows the geographic impact of C van Pottelsberghe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C van Pottelsberghe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C van Pottelsberghe more than expected).

Fields of papers citing papers by C van Pottelsberghe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C van Pottelsberghe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C van Pottelsberghe. The network helps show where C van Pottelsberghe may publish in the future.

Co-authorship network of co-authors of C van Pottelsberghe

This figure shows the co-authorship network connecting the top 25 collaborators of C van Pottelsberghe. A scholar is included among the top collaborators of C van Pottelsberghe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C van Pottelsberghe. C van Pottelsberghe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist 2000 ·European Journal of Cancer ·(unknown), Desmond Curran, Martine Piccart, J.C.J.M. de Haes, P.F. Bruning, J.G.M. Klijn, M. Bontenbal, C van Pottelsberghe, M. Groenvold, Robert Paridaens	49
2	A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients breakdown → 2000 ·European Journal of Cancer ·Kristin Bjordal, Alexander de Graeff, Peter Fayers, Eva Hammerlid, C van Pottelsberghe, Desmond Curran, Marianne Ahlner‐Elmqvist, E.J. Maher, J Meyza, A. Brédart, A.-L. Söderholm, (unknown), Jocelyne S. Feine, Helmut Abendstein, Randall P. Morton, T. Pignon, (unknown), (unknown), S. Kaasa	630
3	Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC lung cancer cooperative group 1997 ·European Journal of Cancer ·Tarek Sahmoud, Pieter E. Postmus, C van Pottelsberghe, K. Mattson, L. Tammilehto, Ted A.W. Splinter, André Planting, Tom G. Sutedja, (unknown), Nico van Zandwijk, Paul Baas, K. J. Roozendaal, (unknown), A. Kirkpatrick, M. van Glabbeke, Andrea Ardizzoni, Giuseppe Giaccone	39
4	Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European organization for research and treatment of cancer, gastrointestinal tract cancer cooperative group) 1996 ·European Journal of Cancer ·(unknown), C van Pottelsberghe, T.C. Kok, B Paillot, T. Wagener, Jacques De Grève, (unknown), B. Gérard, M. van Glabbeke, Harry Bleiberg, (unknown)	2
5	Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. 1996 ·Journal of Clinical Oncology ·Thierry Conroy, Pierre-Luc Etienne, Antoine Adenis, (unknown), B Paillot, Éric François, Laurent Bedenne, J H Jacob, Jean‐François Seitz, Harry Bleiberg, C van Pottelsberghe, M. van Glabbeke, F.M. Delgado, (unknown), J. Wils	68
6	849 Preliminary report of a randomized phase II study comparing two different ifosfamide (IF) regimens in advanced soft tissue sarcoma patients (PTS) failing first-line anthracyclines 1995 ·European Journal of Cancer ·(unknown), Henning T. Mouridsen, (unknown), Ole S. Nielsen, C van Pottelsberghe, M. van Glabbeke, Thomas Tursz	1
7	Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult 1994 ·Annals of Oncology ·(unknown), Jaap Verweij, G. Catimel, M. Clavel, Pierre Kerbrat, A.T. van Oosterom, Joseph Kerger, T Türsz, M. van Glabbeke, C van Pottelsberghe, (unknown), (unknown)	116
8	Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine () in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study 1994 ·European Journal of Cancer ·Jaap Verweij, Ian Judson, William P. Steward, Robert E. Coleman, Penella J. Woll, C van Pottelsberghe, M. van Glabbeke, Henning T. Mouridsen	14
9	Phase II study of miltefosine (Hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult— An EORTC Soft Tissue and Bone Sarcoma Group study 1993 ·European Journal of Cancer ·Jaap Verweij, Krzysztof Krzemieniecki, T.C. Kok, Andrés Poveda, C van Pottelsberghe, M. van Glabbeke, Henning T. Mouridsen	34
10	Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult 1993 ·European Journal of Cancer ·(unknown), Jaco J. Verweij, M. Clavel, G. Catimel, Pierre Kerbrat, N.B. Bui, Joseph Kerger, A. Van Oosterom, T Türsz, M. van Glabbeke, C van Pottelsberghe, Henning T. Mouridsen, N Le Bail	5
11	Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients 1993 ·European Journal of Cancer ·Jacek Jassem, H Karnicka-Młodkowska, C van Pottelsberghe, M. van Glabbeke, (unknown), Andrea Ardizzoni, F Gozzelino, A.S.T. Planting, Nico van Zandwijk	65
12	Selective neuronal, dendritic, and postsynaptic localization of viral antigen in measles-infected mice. 1979 ·PubMed ·C van Pottelsberghe, Kottil Rammohan, H. F. McFarland, M. Dubois-Dalcq	25
13	A kinetic study of the soluble 5′-nucleotidase of rat liver 1977 ·Biochemical Journal ·Greet Van den Berghe, C van Pottelsberghe, H G Hers	110

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact